NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
24 trialsNCT06567782 2026-03-12
AZUR-4
GlaxoSmithKline
Phase 2 Recruiting
NCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06830239 2026-02-12
Superhero
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT07408063 2026-02-12
BeeHive
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04774419 2026-02-03
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06405230 2026-02-03
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07381777 2026-02-02
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT05855200 2026-01-23
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
Phase 3 Recruiting
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT06879717 2026-01-16
PULMO-01
iOnctura
Phase 1/2 Active not recruiting
NCT07336147 2026-01-14
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT06062420 2026-01-09
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03843359 2026-01-08
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05565378 2026-01-08
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05723562 2026-01-08
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT07108270 2025-12-22
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
Phase 2 Recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT05277051 2025-12-19
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting